AI Analysis
AI-generated analysis. Always verify with the original filing.
Net losses narrowed 14.2% to -$19.4M due to reduced other expenses from lower debt settlements and equity issuance losses, despite wider operating deficits of -$16.1M from development activities. Intensified cash burn highlights pre-commercial pressures with liquidity insufficient for 12+ months.
Key Takeaways
1Net loss narrowed 14.2% to -$19.4M as other expenses declined from reduced debt settlements and equity issuance losses.
2Operating loss widened 10.6% to -$16.1M amid ongoing product and clinical development funding needs.
3Operating cash use increased to -$15.2M from -$12.5M, driven by operational requirements for R&D and working capital.
4Diluted EPS improved to $31.22 from $68.44, reflecting share changes despite persistent per-share losses.
5Free cash flow reached -$15.3M with minimal capex of $96K, underscoring heavy reliance on operating cash needs.
6Management states current cash will not fund operating needs for 12+ months as CBGM programs advance.